Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 34.00 | |
25 mg | In stock | $ 55.00 | |
50 mg | In stock | $ 93.00 | |
100 mg | In stock | $ 155.00 | |
500 mg | In stock | $ 389.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 31.00 |
Description | Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis. |
In vivo | In rats subjected to liver transplants, Bucillamine significantly enhances survival and protected against hepatic injury[2]. Subconjunctival injection of Bucillamine significantly reduces the leakage and size of experimental CNV in rats[3]. |
Synonyms | DE-019, Thiobutarit, Tiobutarit, SA96, DE 019, DE019 |
Molecular Weight | 223.31 |
Formula | C7H13NO3S2 |
CAS No. | 65002-17-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (111.95 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bucillamine 65002-17-7 Angiogenesis oxidation-reduction Tyrosine Kinase/Adaptors VEGFR Antioxidant rheumatoid arthritis DE-019 Thiobutarit Ischemia/reperfusion Tiobutarit antioxidant antirheumatic inhibit Inhibitor SA96 SA-96 DE 019 antiangiogenic SA 96 Vascular endothelial growth factor receptor choroidal neovascularization DE019 inhibitor